Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas

NCT03179930 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT03179930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03179930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 7, 2017
Completion date
June 30, 2027
Enrollment
47 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, refractory, relapsed